Concepedia

Publication | Open Access

Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study

DOIFull Paper Access

29

Citations

45

References

2022

Year

Niek A. Peters, Alexander Constantinides, Inge Ubink, Joyce van Kuik, Haiko J. Bloemendal, Joyce M. van Dodewaard, Menno A. Brink, Thijs P. Schwartz, Martijn P. Lolkema, Miangela M. Laclé,
Frontiers in Oncology

Abstract

Imatinib may have value as a CMS-switching drug in primary colon cancer and induces a gene expression program that is associated with improved survival.

References

YearCitations

Page 1